All In Biotech

Drug Trial Radar · NCT05042401

A Trial of SHR-1703 in Asthma

Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of a Single Subcutaneous Injection of SHR-1703 in Patients With Asthma -- a Randomized, Double-blind, Dose-increasing, Placebo Controlled Phase I Clinical Study

Last checked: Nov 19, 2026Latest source record: Apr 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

23

Actual

Start

Oct 12, 2021

Primary completion

Jun 15, 2023

Study completion Jun 15, 2023

Sponsor

Sponsor type
Industry
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in patients with asthma. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics ,pharmacodynamics and immunogenic characteristics of multiple subcutaneous injections of SHR-1703 in asthmatic patients.

Conditions

  • Asthma

Interventions

  • SHR-1703Drug

    SHR-1703 low dose

  • placeboDrug

    placebo low dose

  • SHR-1703Drug

    SHR-1703 high dose

  • placeboDrug

    placebo high dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of adverse events of SHR-1703Time frame: From Day 1 to Day 281
  2. Severity of adverse events of SHR-1703Time frame: From Day 1 to Day 281
  3. Tolerability of adverse events of SHR-1703Time frame: From Day 1 to Day 281

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.